Highly active anti-retroviral therapy use during pregnancy and the risk of mother-to-child transmission, congenital malformation, and neonatal death

怀孕期间使用高效抗逆转录病毒治疗会增加母婴传播、先天畸形和新生儿死亡的风险

• 批准号: 288921
• 负责人: Brard Anick
• 金额: $ 7.29万
• 依托单位: Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
• 依托单位国家: 加拿大
• 项目类别: Miscellaneous Programs
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-06-01 至 2014-06-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=288921&lang=en
• 关键词: Haart Use; Major Congenital Malformations; Mother To Child Transmission; Neonatal Death; Pregnancy

Present data suggest that pregnant HIV women should be treated during gestation to prevent MCTC and neonatal death. However, there is no consensus as to whether treatment should be initiated in the first trimester (when organogenesis occurs) or later (whe

目前的数据表明，艾滋病毒孕妇应在妊娠期间接受治疗，以预防 MCTC 和新生儿死亡。然而，对于是否应该在妊娠早期（器官发生发生时）或稍后（器官发生时）开始治疗，尚未达成共识。